By Don Nico Forbes
Shares in Liquidia rose after the U.S. Supreme Court rejected an appeal by United Therapeutics in the fellow biotech company's patent dispute.
Shares were recently up 12% at $11.20.
The court rejected United's appeal over a decision to invalidate its patent claims concerning Liquidia's drug Yutrepia, with the decision now final and not subject to further appeal, Liquidia said.
United claims the drug infringes on its patent covering the inhaled administration of the drug treprostinil. Yutrepia is an inhaled version of treprostinil. Liquidia sells treprostinil in pills, powder and injections.
On May 31, a U.S. district court had denied United's request for a preliminary injunction.
The U.S. Food and Drug Administration gave tentative approval for Yutrepia to treat adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease in August, the company said. Final approval may occur after the expiration of three-year regulatory exclusivity for Tyvaso DPI on May 23, 2025, it added.
Write to Don Nico Forbes at don.forbes@wsj.com
(END) Dow Jones Newswires
October 07, 2024 10:59 ET (14:59 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.